Anitocabtagene autoleucel
Sponsors
Kite Pharma Inc., Fundacion PETHEMA, Kite, A Gilead Company, PETHEMA Foundation
Conditions
Anitocabtagene AutoleucelDe Novo Multiple MyelomaMultiple MyelomaNewly diagnosed multiple myeloma according to IMWG criteriaRelapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody
Phase 2
A Phase 2, open-label, multicenter multi-cohort study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple myeloma
Active, not recruitingCTIS2024-517020-18-00
Start: 2025-06-30Target: 30Updated: 2025-06-25
Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
RecruitingNCT07045909
Start: 2025-06-30End: 2030-03-31Target: 30Updated: 2025-08-01
Phase 3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
RecruitingNCT06413498
Start: 2024-08-23End: 2031-07-01Target: 450Updated: 2026-03-27
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
RecruitingCTIS2024-511188-26-00
Start: 2024-12-20Target: 192Updated: 2025-09-12